Results 151 to 160 of about 618,942 (290)

IL4I1⁺ Macrophages and TDO2⁺ Myofibroblasts Drive AhR‐Mediated Immunosuppression and Ferroptosis Resistance in Solid Predominant Lung Adenocarcinoma

open access: yesAdvanced Science, EarlyView.
Solid predominant lung adenocarcinoma exhibits an immune‐excluded, ferroptosis‐resistant niche enriched with IL4I1⁺ TAMs and TDO2⁺ myCAFs. Spatial and multi‐omics analyses reveal AhR‐driven crosstalk that promotes T cell exhaustion and therapy resistance. Blocking AhR with CH‐223191 restores ferroptosis sensitivity, and its combination with ferroptosis
Zhaoxuan Wang   +16 more
wiley   +1 more source

HSP70 Interactome‐Mediated Proteolysis Targeting Chimera (HSP70‐PROTAC) for Ferroptosis‐Driven Cancer Treatment

open access: yesAdvanced Science, EarlyView.
This study reports a novel targeted protein degradation strategy termed “HSP70‐PROTAC” that recruits Hsc70 complex to a target protein for inducing degradation. Among them, GDAz‐3 exhibits effective GPX4 degradation activity via UPS/CMA processes, triggering ferroptosis‐driven anticancer activity in vitro and in vivo.
Jinyun Dong   +15 more
wiley   +1 more source

A20 Facilitates Oxaliplatin Sensitivity in Colorectal Cancer Through Monoubiquitylation of IKK‐β

open access: yesAdvanced Science, EarlyView.
This study demonstrates that the expression of A20, a ubiquitin‐editing enzyme, is positively correlated with oxaliplatin sensitivity in colorectal cancer (CRC). Mechanistically, A20 enhances oxaliplatin sensitivity by inhibiting NF‐κB nuclear translocation through monoubiquitination of IKK‐β.
Fan Luo   +12 more
wiley   +1 more source

Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase

open access: yesBrazilian Journal of Medical and Biological Research, 2006
We evaluated the expression of 10 adhesion molecules on peripheral blood tumor cells of 17 patients with chronic lymphocytic leukemia, 17 with mantle-cell lymphoma, and 13 with nodal or splenic marginal B-cell lymphoma, all in the leukemic phase and ...
D.M. Matos   +4 more
doaj  

Spatiotemporally Controlled Tumor Photodynamic/Immunotherapy Therapy Based on Upconversion Hybrid Nanosystem

open access: yesAdvanced Science, EarlyView.
PURH is constructed by a five‐layer upconversion nanoparticle (UCNP) surface coated with mesoporous silica, which encapsulates rose bengal (RB) within the mesoporous channels. Additionally, CpG oligonucleotides (CpG ODN) is linked to the surface, followed by the surface functionalization of hyaluronic acid (HA). This spatiotemporally controllable smart
Fang Wang   +9 more
wiley   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

open access: yesAdvanced Science, EarlyView.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei   +32 more
wiley   +1 more source

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen   +12 more
wiley   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

B-Cell Lymphomas

open access: yes, 2020
Subramanian Kalaivani Selvi   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy